The role of anemia in congestive heart failure and chronic kidney insufficiency - the cardio-renal anemia syndrome

被引:14
作者
Silverberg, DS
Wexler, D
Iaina, A
机构
[1] Tel Aviv Med Ctr & Sch Med, Dept Nephrol, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Med Ctr & Sch Med, Dept Cardiol, IL-64239 Tel Aviv, Israel
[3] Tel Aviv Med Ctr & Sch Med, Heart Failure Unit, IL-64239 Tel Aviv, Israel
关键词
D O I
10.1353/pbm.2004.0072
中图分类号
N09 [自然科学史]; B [哲学、宗教];
学科分类号
01 ; 0101 ; 010108 ; 060207 ; 060305 ; 0712 ;
摘要
Anemia is a major problem in patients with chronic kidney insufficiency. The development of recombinant human erythropoietin has enabled physicians to correct this anemia. Although anemia has not been considered to be a common or important contributor to congestive heart failure, anemia of any cause can lead to cardiac damage and eventually congestive heart failure. Our joint renal-cardiac heart failure team found that anemia was indeed very common in congestive heart failure and was associated with severe, medication-resistant cardiac failure. Correction of the anemia with erythropoietin and intravenous iron led to a marked improvement in patients' functional status and their cardiac function, and to a marked fall in the need for hospitalization and for high-dose diuretics; renal function usually improved or at least stabilized. Subsequent investigations by others have confirmed many of our observations. We call this interrelationship between congestive heart failure, chronic kidney insufficiency, and anemia the Cardio-Renal Anemia syndrome. Treatment of the anemia in congestive heart failure may prove vital in preventing progression of both the heart failure and the associated renal disease.
引用
收藏
页码:575 / 589
页数:15
相关论文
共 49 条
[1]   Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction [J].
Al-Ahmad, A ;
Rand, WM ;
Manjunath, G ;
Konstam, MA ;
Salem, DN ;
Levey, AS ;
Sarnak, MJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (04) :955-962
[2]  
ANAND IS, 1993, BRIT HEART J, V70, P357
[3]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[4]   Relationship between heart failure treatment and development of worsening renal function among hospitalized patients [J].
Butler, J ;
Forman, DE ;
Abraham, WT ;
Gottlieb, SS ;
Loh, E ;
Massie, BM ;
O'Connor, CM ;
Rich, MW ;
Stevenson, LW ;
Wang, YF ;
Young, JB ;
Krumholz, HM .
AMERICAN HEART JOURNAL, 2004, 147 (02) :331-338
[5]  
Collins AJ, 2003, NEPHROL DIAL TRANSPL, V18, P2, DOI 10.1093/ndt/gfg1058
[6]   Influence of target hemoglobin in dialysis patients on morbidity and mortality [J].
Collins, AJ .
KIDNEY INTERNATIONAL, 2002, 61 :S44-S48
[7]   Epoetin alfa for protection of metabolic and exercise capacity in cancer patients [J].
Daneryd, P .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :69-74
[8]   Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial [J].
Hillege, HL ;
van Gilst, WH ;
van Veldhuisen, DJ ;
Navis, G ;
Grobbee, DE ;
de Graeff, PA ;
de Zeeuw, D .
EUROPEAN HEART JOURNAL, 2003, 24 (05) :412-420
[9]  
HILLEGE HL, 1999, J AM SOC NEPHROL, V10, pA384
[10]   Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure [J].
Horwich, TB ;
Fonarow, GC ;
Hamilton, MA ;
MacLellan, WR ;
Borenstein, J .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (11) :1780-1786